Page 7 - Genentech News Today

Currently available flu medications only target the virus after it has already established an infection, but what if a drug could prevent infection in the first place?

After the pandemic shined a spotlight on public health, it remains an in-demand field.

/PRNewswire/ -- Lupus advocates from across the nation converged on Capitol Hill for the National Lupus Advocacy Summit May 19-21. Hosted by the Lupus...

SAN DIEGO — Few patients are evaluated based on all seven endpoints of guidelines indicating complete asthma remission, according to a poster presented at the American Thoracic Society International Meeting. Standardized protocols that include all these domains are needed for accurate assessment of asthma remission, Thomas C. Corbridge, MD, FCCP, U.S. senior medical lead, respiratory

The FDA approved the first 2 biosimilars referencing aflibercept (Eylea). (aflibercept). However, patent litigation has left it unclear when the biosimilars will come to market.

An analysis of global online conversations among health care professionals on social media in April revealed tremendous enthusiasm about FDA approval of a treatment for adults with advanced HER2-positive solid tumors. The FDA granted accelerated approval to fam-trastuzumab deruxtecan-nxki (Enhertu; AstraZeneca, Daiichi Sankyo) — a HER2-directed antibody-drug conjugate previously approved

The designation is based on Phase III INAVO120 results, showing the inavolisib-based regimen more than doubled progression-free survival compared with palbociclib and fulvestrant alone in the...

The designation is based on Phase III INAVO120 results, showing the inavolisib-based regimen more than doubled progression-free survival compared with palbociclib and fulvestrant alone in the first-line

Investor Day 2024 Unlocking growth to 2030 and beyond Speaker biographies Pascal Soriot ...

Two multiple sclerosis experts discuss the implications of a first-ever clinical trial by Genentech designed exclusively to broaden the current...